I Cannot Tell A Lie


I don’t know about you, but I find it difficult to lie. For me, I consider that a good thing. Now, I’m not saying I’ve never lied. If we’re all honest, we’ve all lied. (No pun intended.) However, consider what you are about to read and then ask yourself if you can’t lie or if… you can’t lie. Read on and you’ll understand.

In the early 1900’s, Carl Camp wrote something to the effect that Parkinson’s patients were those who worked hard and who resisted the influence of tobacco and alcohol, among ‘other respectable traits’. Because of these findings, research has been conducted to prove whether or not this is actually an accurate account. The association of PD with personality or behavioral traits have shown over again that PD patients have traits such as being productive, inflexible and passionate about whatever they do. And…they’ve also been described as being honest.

Honest how? They cannot tell a lie. Does that mean that Parkinson’s tends to target honest people? Possibly. It’s been said that certain chemical changes in the brain during the course of the disease may have something to do with it. Another study found that the change in patients was due to the disease rather than aging, and that there may be a possibility that such personality traits are common with PD brain damage.

Does that mean that patients don’t choose to tell a lie but actually find it difficult to lie, due to something beyond their control, such as causes due to change in specific areas of the brain?

While this news may be considered a good benefit of having Parkinson’s disease, I would hope that I would be making the choice to not lie because it’s the right thing to do and not because I have PD. However, I’ll take what I can get and if PD is responsible for upstanding patients, then I’m thankful for that one good thing.

And that’s the truth.

More Info on New PD Drug

AbbVie Announces U.S. FDA Approval of DUOPA™ (carbidopa and levodopa) Enteral Suspension for the Treatment of Motor Fluctuations in Patients with Advanced Parkinson’s Disease

· DUOPA is the first and only treatment providing 16 continuous hours of carbidopa and levodopa for motor fluctuations in advanced Parkinson’s disease

· In a clinical trial, patients treated with DUOPA experienced significantly greater improvement in “off” time than patients treated with oral carbidopa-levodopa immediate release tablets

NORTH CHICAGO, Ill. January 12, 2015 – The U.S. Food and Drug Administration (FDA) has approved AbbVie’s (NYSE: ABBV) DUOPA™ (carbidopa and levodopa) enteral suspension for the treatment of motor fluctuations for people with advanced Parkinson’s disease. DUOPA is administered using a small, portable infusion pump that delivers carbidopa and levodopa directly into the small intestine for 16 continuous hours via a procedurally-placed tube.

DUOPA was approved by the FDA as an orphan drug, a designation granted to products intended for the treatment of rare diseases or conditions affecting fewer than 200,000 patients in the U.S.

“There is unmet need for treatment options for patients with advanced Parkinson’s disease. As the disease advances, it can be difficult to control motor features,” said C. Warren Olanow, M.D., Professor, Department of Neurology and Department of Neuroscience, Mount Sinai School of Medicine, and lead investigator of the DUOPA pivotal trial. “In clinical trials, DUOPA was shown to significantly reduce the amount of off time advanced Parkinson’s disease patients experienced.”

In the advanced stages of Parkinson’s disease, patients may begin to experience “off” time, or periods of poor mobility, slowness and stiffness. Additionally, in Parkinson’s disease patients, the spontaneous emptying of the stomach becomes delayed and unpredictable, which can affect the timing of when orally administered medicines leave the stomach and are absorbed in the small intestine. DUOPA provides patients with the same active ingredients as orally-administered carbidopa and levodopa immediate release, but is delivered in a suspension that goes directly into the small intestine via a tube placed by a percutaneous endoscopic gastrostomy procedure with jejunal extension (PEG-J). This type of administration is intended to bypass the stomach.

“The FDA approval of DUOPA is another significant milestone for AbbVie’s pipeline,” said Michael Severino, M.D., Executive Vice President, Research and Development and Chief Scientific Officer, AbbVie. “This advancement is important for patients with advanced Parkinson’s disease and their care teams, as it provides a new therapeutic option to help manage motor symptoms.”

“Due to the progressive nature of Parkinson’s disease, it can be difficult to treat over time, especially in the advanced stages,” said Joyce Oberdorf, President and CEO, National Parkinson Foundation. “Our organization is encouraged by the introduction of a new therapy that may provide another treatment option for affected patients and families.”

Good News!


FDA Approves RYTARY for Treatment of Parkinson’s Disease

– Jan 08 2015

The Parkinson’s Disease Foundation (PDF) alerts the community that RYTARYTM, an extended release formulation of carbidopa/levodopa, has been approved by the US Food and Drug Administration (FDA) for the treatment of Parkinson’s disease. The approval was announced today by the drug’s manufacturer, Impax Pharmaceuticals.

Among the medications available to treat Parkinson’s disease, carbidopa/levodopa, often taken as Sinemet(R), remains the gold-standard for easing motor symptoms. But as Parkinson’s disease advances, the drug becomes effective for shorter time periods. This often makes it necessary for people with Parkinson’s disease to take the carbidopa/levodopa four or more times a day to control symptoms.

Even then, people with PD taking the drug experience drops in their levels of levodopa, causing a worsening of motor symptoms as the drug “wears off.”

In recent years, drug manufacturers have tried to develop a formulation of carbidopa/levodopa that would release more slowly over time, and keep levodopa levels more even, thus reducing “off times” for people with Parkinson’s disease. The manufacturer of RYTARYTM states that the drug is designed to reduce off times in people with Parkinson’s disease.

“A new drug for PD is always a cause for celebration. RYTARYTM is formulated to kick in rapidly, then maintain blood levels longer than immediate-release carbidopa/levodopa,” says Kathleen M. Shannon, M.D., Chair of PDF’s Medical Policy Committee and Professor of Neurology at the PDF Research Center at Rush University Medical Center. “This makes it potentially useful for people with Parkinson’s who are having wearing off of drug benefit between doses.”

The manufacturer has announced its expectation for the drug to be available in February 2015 in four strengths. The dose of RYTARYTM must be adjusted carefully as there is not a simple 1:1 relationship between the dose of carbidopa/levodopa and that of RYTARYTM. People with Parkinson’s disease who are interested in RYTARYTM are advised to discuss with their doctors the potential risks and benefits of the drug in comparison with other PD drugs.

PDF welcomes the addition of this new tool for clinicians and people with Parkinson’s disease. For additional information about medications for Parkinson’s disease, please contact PDF’s HelpLine at (800) 457-6676 or info@pdf.org or use our free resources below.

Download Fact Sheet: Understand PD Medications

View PD ExpertBriefing: Medication Side Effects

View PD ExpertBriefing: Managing the Motor Symptoms of PD

Related Posts Plugin for WordPress, Blogger...